Intravenous Iron Therapy Guidelines

Indications for Intravenous Iron

The American Gastroenterological Association recommends intravenous iron for patients who cannot tolerate oral iron, have conditions where oral iron absorption is impaired, or have failed to respond to oral iron therapy, as blood transfusions are rarely indicated for iron deficiency anemia and should be reserved only for severe symptomatic anemia with hemodynamic instability 1
The American Society of Hematology suggests that blood transfusions should be used rarely in iron deficiency anemia, as they carry significant risks including thrombosis, infection, and increased mortality, while providing only temporary hemoglobin improvement without addressing the underlying iron deficit 2
Intravenous iron is indicated for patients with oral iron intolerance or failure, as evidenced by gastrointestinal side effects or failure to improve ferritin levels after an adequate trial of oral iron therapy 1
If hemoglobin does not increase by at least 10 g/L after 2 weeks of daily oral iron, this predicts subsequent treatment failure with a sensitivity of 90.1% and specificity of 79.3% 3

The American Gastroenterological Association recommends intravenous iron for post-bariatric surgery patients with iron deficiency anemia and no identifiable GI blood loss, as duodenal iron absorption is disrupted 1
Intravenous iron is indicated for patients with inflammatory bowel disease and active inflammation, as well as those with celiac disease and other malabsorptive disorders where oral iron is unlikely to be absorbed effectively 1

The National Comprehensive Cancer Network defines absolute iron deficiency as ferritin <30 ng/mL and transferrin saturation <15%, requiring iron repletion 4
The American Society of Hematology recommends intravenous iron over transfusion for moderate-to-severe iron deficiency anemia in cancer patients not on chemotherapy 2

The National Comprehensive Cancer Network recommends intravenous iron in combination with erythropoiesis-stimulating agents for cancer patients on chemotherapy with ferritin ≤800 ng/mL and transferrin saturation <20% 4
The American Society of Hematology suggests monitoring iron indices, including ferritin and transferrin saturation, at baseline and periodically in cancer patients 5, 6

The American Gastroenterological Association prefers single or two-dose regimens over multiple-dose regimens for patient convenience and compliance 1
Low-molecular-weight iron dextran is preferred over high-molecular-weight formulations due to lower anaphylaxis risk 4

The American Gastroenterological Association notes that true anaphylaxis is very rare with modern IV iron formulations, and most reactions are complement activation-related pseudo-allergy 1
Iron sucrose has the lowest reported anaphylaxis risk, with 24 cases per 100,000 patients 7
The National Comprehensive Cancer Network recommends observing patients for at least 30 minutes after administration and until clinically stable 4

The National Comprehensive Cancer Network lists active infection as a theoretical concern, although not confirmed in critical care patients, and known hypersensitivity to IV iron or its components as contraindications 4, 7